1-(1-benzyl-4-piperidyl)-2(1H)-quinolinone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(1-benzyl-4-piperidyl)-2(1H)-quinolinone
• 英文别名: 1-(1-benzyl-4-piperidinyl)carbostyril；1-(1-benzylpiperidin-4-yl)quinolin-2-one
• 化学式: C₂₁H₂₂N₂O
• 分子量: 318.418
• InChiKey: AEOKFQUAWXUIHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-苯胺-1-苯甲基哌啶 在 硫酸 、 三乙胺 作用下， 以 异丙醚 为溶剂， 反应 1.5h， 生成 1-(1-benzyl-4-piperidyl)-2(1H)-quinolinone
  参考文献：
  名称：

  Orally active, nonpeptide vasopressin V1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihydro-2(1H)-quinolinones

  摘要：

  A series of compounds has been synthesized and demonstrated to be antagonists of V1 receptors both in vitro and in vivo. These compounds are structurally related to the 1-(4-piperidyl)-2(1H)-quinolinones, including OPC-21268, an orally bioavailable AVP V1 antagonist with high V1 specificity. It has been found that the introduction of an acetamide group on the terminal alkoxy chain of 41-44 leads to an increase in oral activity. Certain of these compounds may have efficacy in the study of AVP V1 receptors.

  DOI：

  10.1021/jm00066a010

文献信息

• Carbostyril derivatives
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0382185B1

  公开（公告）日：1994-06-15
• US5225402A
  申请人：——

  公开号：US5225402A

  公开（公告）日：1993-07-06
• US5436254A
  申请人：——

  公开号：US5436254A

  公开（公告）日：1995-07-25
• US5652247A
  申请人：——

  公开号：US5652247A

  公开（公告）日：1997-07-29
• Orally active, nonpeptide vasopressin V1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihydro-2(1H)-quinolinones
  作者：Hidenori Ogawa、Yoshitaka Yamamura、Hisashi Miyamoto、Kazumi Kondo、Hiroshi Yamashita、Kenji Nakaya、Tomihiko Chihara、Toyoki Mori、Michiaki Tominaga、Youichi Yabuuchi

  DOI：10.1021/jm00066a010

  日期：1993.7

  A series of compounds has been synthesized and demonstrated to be antagonists of V1 receptors both in vitro and in vivo. These compounds are structurally related to the 1-(4-piperidyl)-2(1H)-quinolinones, including OPC-21268, an orally bioavailable AVP V1 antagonist with high V1 specificity. It has been found that the introduction of an acetamide group on the terminal alkoxy chain of 41-44 leads to an increase in oral activity. Certain of these compounds may have efficacy in the study of AVP V1 receptors.